Evidence map›Paper›PMID 41941080›Full record

ArticleJournal of robotic surgery2026

Device malfunctions and patient harm in robotic-assisted prostatectomy: a 17-year review of the FDA MAUDE database.

Bara M Hammadeh, Ayham Mohammad Hussein, Nesreen Alhamwi, AlBaraa K Mohammad, Rami Ghanem

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Open vs. robotic prostatectomy using VersiusJournal of robotic surgery · 2026
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bara M HammadehAl-Balqa' Applied University, Salt, Jordan. Barahammadeh2005@gmail.com.ORCID http://orcid.org/0009-0002-1025-1068
Ayham Mohammad HusseinAl-Balqa' Applied University, Salt, Jordan.ORCID http://orcid.org/0009-0006-3277-1549
Nesreen AlhamwiThe University of Jordan, Amman, Jordan.ORCID http://orcid.org/0009-0009-3015-3669
AlBaraa K MohammadAl-Balqa' Applied University, Salt, Jordan.ORCID http://orcid.org/0009-0003-0420-6516
Rami GhanemDepartment of Urology-Oncology, King Hussein Cancer Center, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Robot-assisted radical prostatectomy (RARP) is the predominant surgical treatment for localized prostate cancer. However, postmarket surveillance of device-related adverse events is critical, as robotic systems entered the market through pathways requiring less extensive premarket clinical testing. This study analyzes device malfunctions and patient harm associated with RARP reported to the FDA’s MAUDE database over a 17-year period. We conducted a retrospective analysis of the MAUDE database from 2009 to March 2026. All reports related to prostatectomy using the Da Vinci surgical system were extracted and analyzed descriptively across three system models (Si, Xi, and SP). Device and patient problem frequencies were calculated, and a co-occurrence network analysis was performed to identify commonly associated device issues. Of 11,190 retrieved reports, 1,080 were related to prostatectomy and included. Across the three systems, the most common device malfunction was “Visual Prompts will not Clear,” accounting for 33.3% of Xi reports, 22.4% of SP reports, and 22.4% of Si reports, followed by “Output Problem” (17.6% for Xi, 12.9% for SP and Si). Network analysis revealed a strong co-occurrence between “Defective Component” and “Device Displays Incorrect Message” (Weight = 14 for Xi), suggesting a recurrent hardware-software failure mode consistent across platforms. Patient harms were most frequently reported as “Unspecified Tissue Injury” (31.5% for Xi, 38% for both SP and Si) and “Hemorrhage/Bleeding” (14.2% for Xi). The mortality rate among reported events was approximately 0.8–0.9%. This 17-year analysis reveals a 3.5% device malfunction rate in RARP, with a distinct pattern of software-interface and output problems persisting across the Xi, SP, and Si systems. While most patient harms align with known procedural risks, the co-occurrence of specific device failures points to systematic vulnerabilities that transcend individual system models. The Si system showed a unique profile of device problems related to electronic properties and incorrect display messages, alongside a higher proportion of severe patient outcomes in reported events. These findings highlight the need for enhanced preoperative system checks, improved surgeon training in malfunction management, and the development of more robust prospective surveillance systems to complement passive reporting.

Indexed as

Equipment FailureProduct Surveillance, PostmarketingProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresDatabases, FactualHumansMaleRetrospective StudiesUnited StatesUnited States Food and Drug AdministrationDa Vinci Surgical SystemDevice malfunctionMAUDE databasePatient safetyPostmarket surveillanceRobotic-assisted prostatectomyUrologic surgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.